On February 3, 2026, Ultragenyx Pharmaceutical announced promising long-term data from clinical studies for UX111, showing substantial improvements in cognitive and functional abilities in children with Sanfilippo syndrome type A, with a significant reduction of 63.98% in cerebrospinal fluid heparan sulfate levels.